Nivolumab combined with Ipilimumab followed by curative-intent surgery was evaluated as a treatment strategy for patients with locoregional relapse of Melanoma after adjuvant therapy in a study presented at the ESMO Sarcoma and Rare Cancers Congress 2026. The analysis explored outcomes in this rare clinical setting, where evidence guiding management after failure of adjuvant treatment remains limited.
Authors: Anna Mariuk-Jarema, Pawel Teterycz , Karolina Sosnowska, Hanna Kosela-Paterczyk, Pawel Rogala, Katarzyna Kozak, Anna M. Szumera-Cieckiewicz, Piotr Rutkowski
Background
Immune checkpoint inhibitors and targeted therapies with BRAF and MEK inhibitors have become standard treatments for Melanoma across several disease stages. However, the optimal management of patients who develop…